Andrew Scott
17Patents
5h-index
41Co-inventors
62Inventor score
Filing activity: May 13, 2002 → Feb 27, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7589180B2 | Specific binding proteins and uses thereof | Chemistry; Metallurgy | 37 | Expired |
| US7767792B2 | Antibodies to EGF receptor epitope peptides | Human Necessities | 23 | Active |
| US7381801B2 | Chimerized GM-CSF antibodies | Chemistry; Metallurgy | 19 | Expired |
| US8652473B2 | Antibodies to EGF receptor epitope peptides and uses thereof | Human Necessities | 8 | Active |
| US9169329B2 | Antibodies directed to the receptor tyrosine kinase c-Met | Chemistry; Metallurgy | 5 | Active |
| US7714113B2 | Fusion proteins of humanized g250 specific antibodies and uses thereof | Chemistry; Metallurgy | 2 | Expired |
| US12201647B2 | Inducing caspase activity | Human Necessities | 0 | Active |
| US9528034B2 | Cyanoacrylate compositions | Chemistry; Metallurgy | 0 | Active |
| US12350288B2 | Inducing caspase activity | Human Necessities | 0 | Active |
| US11352420B2 | Methods and compositions for PDGF-CC inhibition | Chemistry; Metallurgy | 0 | Active |
| US8637016B2 | EphA3 antibodies for the treatment of solid tumors | Chemistry; Metallurgy | 0 | Active |
| US11160873B2 | Anti-metalloprotease antibody for diagnosis and treatment of cancers | Chemistry; Metallurgy | 0 | Active |
| US7897743B2 | Humanized GM-CSF antibodies | Chemistry; Metallurgy | 0 | Active |
| US10023653B2 | Anti-metalloprotease antibody for diagnosis and treatment of cancers | Physics | 0 | Active |
| US12251399B2 | Inducing caspase activity | Human Necessities | 0 | Active |
| US9283276B2 | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US9023356B2 | Treatment method using EGFR antibodies and SRC inhibitors and related formulations | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.